Spain (ES)

Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from completed dose escalation in study 008 (2021) Eigentler T, Heinzerling L, Krauss J, Weishaupt C, Ochsenreither S, Lebbe C, Mohr P, et al. Conference contribution Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) plus palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study (2021) Hurvitz SA, Park YH, Bardia A, Quiroga V, Lopez-Valverde V, Steinseifer J, Moore HM, et al. Conference contribution COVID-19 pandemic impact on healthcare professionals treating patients with neuroendocrine tumors (NET): An international NET CONNECT survey (2021) Hernando J, Lamarca A, Cives M, Caplin ME, Pavel ME Conference contribution Neutral sphingomyelinase mediates the co-morbidity trias of alcohol abuse, major depression and bone defects (2021) Kalinichenko L, Mühle C, Jia T, Anderheiden F, Datz M, Eberle AL, Eulenburg V, et al. Journal article LOST IN THE QUEST FOR FLINT: A GRAVETTIAN HUNTING CAMP (USATEGI, BASQUE COUNTRY) (2021) Calvo A, Arrizabalaga A Journal article ICDAR 2021 Competition on On-Line Signature Verification (2021) Tolosana R, Vera-Rodriguez R, Gonzalez-Garcia C, Fierrez J, Rengifo S, Morales A, Ortega-Garcia J, et al. Conference contribution Accelerated bioactive behavior of Nagelschmidtite bioceramics: Mimicking the nano and microstructural aspects of biological mineralization (2021) Rincón-López JA, Hermann-Muñoz JA, Cinca-Luis N, Fernández-Benavides DA, García-Cano I, Guilemany-Casadamon JM, Boccaccini AR, et al. Journal article Outcomes of 10,312 patients treated with everolimus-eluting bioresorbable scaffolds during daily clinical practice – results from the European Absorb Consortium (2021) Wiebe J, Hofmann FJ, West N, Baumbach A, Carrie D, Bermudez EP, Cayla G, et al. Journal article Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024] (Annals of Oncology (2021) 32(8) (1015–1024), (S0923753421015532), (10.1016/j.annonc.2021.05.353)) (2021) Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, et al. Journal article, Erratum Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial (2021) Brown JP, Engelke K, Keaveny TM, Chines A, Chapurlat R, Foldes AJ, Nogues X, et al. Journal article